Dr. Patrick Page

Dr. Patrick Page

Preclinical Development


Patrick is an accomplished R&D professional and entrepreneur with more than 22 years international experience in private and publicly listed pharmaceutical companies.

He has broad expertise which encompasses multiple therapeutic areas, in large indications as well as rare orphan disease, with main focus in cancer, inflammation, respiratory, metabolic and cardiovascular diseases, neurodegenerative diseases and reproductive health. Patrick has an established track record of leading more than 20+ projects through key scientific, regulatory and partnership milestones which yielded several compounds in late clinical stage such as Nolasiban, OBE-022 and Setanaxib. He served in leadership and executive positions at Astrazeneca and Serono Pharmaceuticals. He led as CSO/CEO the business and scientific strategy of Genkyotex and Epiremed. 

Patrick  is currently CEO of Conicmeds, scientific advisor for the Brussels South Charleroi Biopark and pharmaceutical consultant general manager of Decode Pharma Partners. 

He holds a MSc in Biochemistry, a PhD in Chemistry of biomolecules from the University of Toulouse and a MBA from INSEEC Paris. He is co-author of 20+ patents.